Perspective Therapeutics CATX
NYSE CATX
$2.30 0.00 (-0.19%)
As of: Oct 21, 2026 · 3:39 PM EDT

Perspective Therapeutics (CATX) Construction in Progress (2011)

Updated

Perspective Therapeutics (CATX) reported Construction in Progress of $123,613 for Q4 2011.

Analysis

Perspective Therapeutics (CATX) Construction in Progress (2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,137.42 Bn 1,106.00 Bn 19.71 Bn -
2 Johnson & Johnson 617.98 Bn 536.51 Bn 17.26 Bn -
3 AbbVie 502.80 Bn 475.92 Bn 12.70 Bn -
4 Merck 368.67 Bn 323.05 Bn 12.21 Bn -
5 Novartis Ag 298.36 Bn 262.35 Bn 11.24 Bn -
6 Astrazeneca 261.17 Bn 234.85 Bn 12.86 Bn -
7 Amgen 237.18 Bn 192.58 Bn 7.24 Bn -
8 Gilead Sciences 191.11 Bn 165.31 Bn 6.22 Bn -
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn -
10 Perspective Therapeutics 276.89 Mn 39.99 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2011 123,613.00
API Access

Perspective Therapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=CATX&period=max&api_key=YOUR_API_KEY